表紙
市場調查報告書
商品編碼
390869

全球蛋白質工程市場:各產品類型、技術、終端用戶、地區 - 成長、趨勢、預測(2018年∼2023年)

Protein Engineering Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球蛋白質工程市場,預計從2018年到2023年的調查期間記錄15.8%的年複合成長率。對勝過基因治療的蛋白質療法的關注,及未來生物製藥的專利到期,導致開發中國家的蛋白質工程的需求。

本報告提供全球蛋白質工程市場相關調查,市場概要,各產品類型、技術、終端用戶、地區的市場趨勢,市場規模的變化與預測,市場佔有率,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,市場機會,課題分析(DROC)

  • 市場成長要素
    • 蛋白質缺乏症的增加
    • 化學流程的替代技術的需求增加
    • 蛋白質醫藥品的採用增加
    • 政府對蛋白質工程的出資增加
  • 市場阻礙因素
    • 策略化流程的專家不足
    • 成本高
  • 市場機會
  • 主要課題

第7章 蛋白質工程市場:各市場區隔

  • 各產品類型
    • 改變蛋白質
    • 修飾酵素
    • 胰島素
    • 單株抗體
    • 血液因子
    • 組織型胞漿素原活性化因子
    • 嵌合蛋白
    • 其他
  • 各技術
    • 合理蛋白質設計
    • 無理蛋白質設計
  • 各終端用戶
    • 製藥、生物科技企業
    • 學術機構
    • CRO(醫藥品開發受託機關)
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • 合併、收購分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要業者

  • Thermo Fisher Scientific
  • Eli Lilly and Company
  • Sigma-Aldrich Corporation
  • PerkinElmer, Inc.
  • Bruker Corporation
  • Agilent Technologies
  • Bio-Rad Laboratories, Inc.
  • Waters Corporation
  • Amgen
  • Novo Nordisk

第10章 市場未來展望

目錄
Product Code: 48243

The propelling factors for the growth of the global protein engineering market include the increasing prevalence of protein-deficient diseases, the increase in adoption of protein drugs over non-protein drugs, increased demand for alternatives to chemical processes, and rising government funding for protein engineering.

Protein-energy malnutrition (PEM) is increasing in the rural areas of emerging economies. It refers to a group of disorders that include marasmus, kwashiorkor, and intermediate states of marasmus-kwashiorkor. Therefore, the prevalence of kwashiorkor varies across geographies. It is rare in the United States. However, some of the affected regions include Southeast Asia, Central America, Congo, Puerto Rico, Jamaica, and South Africa. Thus, the increasing prevalence of protein-deficient diseases is driving the demand for the overall market.

There is a rising number of government initiatives, such as funding R&D for protein engineering and awareness programs, which influenced the healthcare industry. Thus, the government is proactively investing in many of the research studies. For instance, Protein Technologies Ltd (PTL) received funding from the UK government's Technology Strategy Board (now Innovate UK), for its innovative research in protein engineering. Hence, the increasing number of government initiatives for the efficient protein engineering research helps in driving the overall growth of the market.

Protein engineering also holds an immense opportunity in the agrochemical industry, as engineering in proteins may lead to the generation of enzymes with improved function, that may increase the crop yield or facilitate the biofuel production. It is also likely to play an important role as a tool, to attain increased crop yield needed to meet future demands.

Key Market Trends

Monoclonal Antibodies by Protein Type is Expected to be Largest Contributor in the Market over the Forecast Period

Monoclonal antibodies are anticipated to hold the largest market share over the forecast period, owing to their high adoption for numerous therapies, such as cancer and autoimmune diseases. The increasing prevalence of cancer and other autoimmune diseases has significantly increased the use of monoclonal bodies for the treatment of diseases. They also have tremendous applications in the fields of therapeutics, diagnostics, and targeted drug delivery systems, for infectious diseases caused by viruses, bacteria, protozoa, metabolic and hormonal disorders. Hence, recombinant deoxyribonucleic acid technology, through genetic engineering, has successfully led to the possibility of reconstruction of monoclonal antibodies, in turn, fueling the growth of the segment.

Asia-Pacific Witnessed the Fastest Growth and is Expected to Follow the Same Trend over the Forecast Period

Asia-Pacific is expected to witness the fastest CAGR during the forecast period, owing to the growing presence of contract research organizations, rising healthcare IT spending, and unprecedented evolution of the healthcare infrastructure and standards across the region. Growing demand for personalized medicine and strong R&D investments in proteomics-based drug discovery projects are also supplementing the growth of the protein engineering market.

Competitive Landscape

The protein engineering market players are highly focused on strategies, such as mergers and acquisitions, new product development initiatives, and geographical expansion. As the cost of R&D is high and requires high-end infrastructure, most of the pharmaceutical and biotechnology companies are moving toward CROs. Most of the players in the CRO industry are joining forces, in order to create a market position.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Protein-deficient Diseases
    • 4.2.2 Increased Demand for Alternatives to Chemical Processes
    • 4.2.3 Increase in Adoption of Protein Drugs over Non-protein Drugs
    • 4.2.4 Rising Government Funding for Protein Engineering
  • 4.3 Market Restraints
    • 4.3.1 Lack of Experts to Strategize the Process
    • 4.3.2 High Costs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Insulin
    • 5.1.2 Monoclonal Antibodies
    • 5.1.3 Coagulation Factors (Blood Factors + Tissue Plasminogen)
    • 5.1.4 Vaccines
    • 5.1.5 Growth Factors (Hormones + Cytokine)
    • 5.1.6 Other Product Types
  • 5.2 By Technology
    • 5.2.1 Irrational Protein Design
    • 5.2.2 Rational Protein Design
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biotechnology Companies
    • 5.3.2 Academic Institutions
    • 5.3.3 Contract Research Organizations (CROs)
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 Bruker Corporation
    • 6.1.4 Bio-Rad Laboratories Inc.
    • 6.1.5 Eli Lilly and Company
    • 6.1.6 Merck KGaA
    • 6.1.7 Novo Nordisk AS
    • 6.1.8 PerkinElmer Inc.
    • 6.1.9 Thermo Fisher Scientific Inc.
    • 6.1.10 Waters Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS